Comparison · NCT01376310-sae
Cohort A (GSK1120212 < 24 Weeks) vs Cohort B (GSK1120212 >= 24 Weeks): serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Cohort A (GSK1120212 < 24 Weeks) vs Cohort B (GSK1120212 >= 24 Weeks): serious adverse events. Trial comparisons, record NCT01376310-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01376310-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.206 | 0.145 | 0.285 | wilson | |
| Risk in group 2 | 0.394 | 0.247 | 0.563 | wilson | |
| Risk difference, group 1 minus group 2 | -0.188 | -0.368 | -0.0207 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.524 | 0.304 | 0.903 | log | |
| Odds ratio, group 1 over group 2 | 0.4 | 0.176 | 0.909 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Cohort A (GSK1120212 < 24 Weeks) than on Cohort B (GSK1120212 >= 24 Weeks) | 5.33 | 2.72 | 48.3 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Cohort A (GSK1120212 < 24 Weeks) | Subjects on GSK1120212 Monotherapy and have been treated less than 24 weeks in their parent study. | 26 | 126 | EG000 |
| Group 2 | Cohort B (GSK1120212 >= 24 Weeks) | Subjects on GSK monotherapy who have been treated for 24 weeks or greater in their parent study. Also, subjects entering this study from any GSK1120212 combo trial. | 13 | 33 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- From date of transition into this Rollover study until 30 days following the last dose (up to 76 months from date of transition).
Source ClinicalTrials.gov
Trial
- Title
- GSK1120212 Rollover Study
- NCT number
- NCT01376310
- Phases
- PHASE2
- Conditions
- Cancer
- Interventions
- GSK1120212, Docetaxel + GSK1120212, Erlotinib + GSK1120212, Pemetrexed + GSK1120212, Carboplatin + GSK1120212, Nab-paclitaxel + GSK1120212, Gemcitabine + GSK1120212, Everolimus + GSK1120212
- Lead sponsor
- Novartis Pharmaceuticals
- Results first posted
- 2019-02-19
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01376310?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01376310-sae